SUBLIVAC Birch Prospective, Randomized, Open, Blinded Endpoint (PROBE) Study.
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2012
At a glance
- Drugs Allergy immunotherapy; Birch pollen allergy immunotherapy
- Indications Asthma; Hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- 15 Mar 2012 Actual patient numbers amended from 74 to 80 as reported by European Clinical Trials Database record.
- 06 Feb 2012 Actual patient number (74) added as reported by ClinicalTrials.gov.
- 15 Sep 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.